**Brussels**: Greek MEP Nikos Papandreou discusses the implications of U.S. tariffs on the European pharmaceutical industry, arguing it could spur EU strategic autonomy and enhance healthcare resilience through measures like the Critical Medicines Act and innovation-focused legislation.
The Trump administration’s approach to tariffs and trade has prompted significant discussion regarding its potential implications for the European Union’s resilience, particularly in the realm of pharmaceuticals. Nikos Papandreou, a Greek Member of the European Parliament (MEP) representing the Socialists and Democrats (S&D), spoke to EURACTIV about the situation and suggested that the tariffs could inadvertently create opportunities for the EU to enhance its strategic autonomy.
Papandreou expressed concern regarding Washington’s increasing efforts to repatriate pharmaceutical production, noting how this might adversely affect the EU’s competitiveness. He remarked, “These protectionist policies may push the EU to strengthen its industrial base, particularly in critical pharmaceutical sectors, as it could lead to increased competition and higher costs for EU pharmaceutical companies.”
The MEP highlighted the necessity for adjustments in pharmaceutical legislation to benefit from any fallout from the Trump administration’s tariff strategy. He suggested that if the U.S. opts for an inward focus, the EU should adapt its pharmaceutical framework to attract investment and enhance the security of its supply chains. Key strategies he outlined include incentivising research and development (R&D), boosting manufacturing within the EU, establishing public-private partnerships, and expanding trade agreements.
Papandreou contended that by refining its approach, the EU could potentially convert U.S. protectionist measures into advantages that would reinforce its global position in health innovation. He noted, “It could inspire others with its potential.”
At a recent meeting in Brussels, the importance of health security was a major topic, with Papandreou spotlighting the Critical Medicines Act (CMA) as a vital initiative aimed at addressing the EU’s increasing dependency on external suppliers for essential pharmaceuticals. He stated, “The increasing reliance on imports from Asia for active pharmaceutical ingredients (APIs) and finished medicines has left Europe vulnerable to supply chain disruptions, price volatility, and geopolitical risks.”
Papandreou called for effective implementation of the CMA, asserting that its success is contingent on sufficient investment, regulatory efficiency, and strong coordination among EU member states. He stated, “If well implemented, the CMA could enhance local production, improve supply chain resilience, and ensure the availability and affordability of critical medicines for all EU citizens.”
The proposal also aims to bolster joint procurement and strategic stockpiling of essential medicines, the MEP mentioned. “Still, its impact will rely on how effectively it integrates with the broader pharmaceutical legislation reform and ensures long-term sustainability and competitiveness,” he added.
Challenges pertaining to shortages, high implementation costs, and regulatory burdens remain a concern, as they could potentially hinder innovation and deter private investment. Papandreou underscored that the transition of production back to the EU would not be immediate and would require careful coordination. He noted that to meet its objectives, the CMA must be aligned with broader reforms in EU pharmaceutical legislation to guarantee streamlined regulations and equitable access.
Papandreou also discussed the Life Science Strategy and the Biotech Act, highlighting their role in boosting innovation, attracting investment, and strengthening EU pharmaceutical sovereignty. He remarked that these initiatives could lead to R&D growth and job creation, notably benefiting countries like Greece. However, he cautioned against risks such as regulatory complexity and global competition, emphasising the necessity for a balanced regulatory framework and strategic investment.
In the context of enhancing healthcare systems, Papandreou noted the potential of the Competitiveness Compass to boost efficiency, innovation, and resilience. He advocated for a focus on digital transformation and data-driven decision-making, which could involve investing in health technology and artificial intelligence (AI) to improve healthcare management.
According to Papandreou, health access should transcend political divides, asserting that decisions affecting the lives of millions should foster a united response across party lines. He expressed concern about the current state of cardiovascular health and mentioned four major preventable mortality risks: tobacco use, alcohol abuse, fossil fuels, and unhealthy diets. He stated, “We must increase our efforts in prevention before treatment.”
Furthermore, he addressed the mental health crisis affecting young populations, noting the substantial economic costs and human toll associated with mental health issues. He highlighted the importance of destigmatising mental health, increasing literacy about it, and amplifying first-line responses and treatment resources.
Source: Noah Wire Services
Subscribe to Industry Updates
